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a b s t r a c t
The advent of highly active antiretroviral therapy (HAART), which constitutes HIV protease inhibitors,
nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and
nucleotide reverse transcriptase inhibitors, has dramatically reduced the morbidity and mortality asso-
ciated with human immunodeﬁciency virus (HIV) infection in resource-rich countries. However, this
disease still kills several million people each year. Though the reason for therapeutic failure is multi-
factorial, an important concern is the treatment and control of HIV within the central nervous system
(CNS). Due to the restricted entry of anti-HIV drugs, the brain is thought to form a viral sanctuary site. This
not only results in virological resistance, but also is often associated with the development of complica-
tions such as HIV-associated dementia. The CNS delivery of anti-HIV drugs is limited by the blood–brain
and blood–CSF interfaces due to a combination of restricted paracellular movement, powerful metabolic
enzymes and numerous transporters including members of the ATP binding cassette (ABC) and solute
carrier (SLC) superfamilies. A better appreciation of the transporters present at the brain barriers will
prove a valuable milestone in understanding the limited brain penetration of anti-HIV drugs in HIV and
also aid the development of new anti-HIV drugs and drug combinations, with enhanced efﬁcacy in the
CNS. This review aims to summarise current knowledge on the transport of anti-HIV drugs across the
blood–brain barrier and the choroid plexus, as well as provide recommendations for future research.
© 2009 Elsevier B.V.
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Table 2
A simple scheme to rank CSF-penetrating drugs or the CNS-penetration effective-
ness (CPE) ranks, proposed by Letendre et al. (2008a). Rank based on the drug
physicochemical characteristics,measuredCSF concentrations andCNSefﬁcacydata
extracted from publicly available information.
Low Intermediate High
Tenofovir (PMPA) Stavudine (d4T) Zidovudine (AZT)
Didanosine (ddI) Lamivudine (3TC) Abacavir
Zalcitabine (ddC) Emtricitabine (FTC) Delavirdine
Nelﬁnavir Efavirenz Nevirapine
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. Introduction
Initially recognised in a handful of cases during the early 1980s,
uman immunodeﬁciency virus (HIV) has infected an estimated 33
illion people worldwide (UNAIDS Epidemic Update, 2008), caus-
ng the acquired immunodeﬁciency syndrome (AIDS). In 2007 the
IV/AIDS epidemic killed approximately 2 million individuals. The
entral nervous system (CNS) is a major target of HIV, becoming
nfected in the primary stage of infection and this continues in
he majority of untreated seropositive individuals throughout the
ourse of infection.
HIV infection in the CNS is associated with the development
f asymptomatic neurocognitive impairment, HIV-associated mild
eurocognitive disorder (MND), and eventually HIV-associated
ementia (HAD) or AIDS dementia complex that manifests as a
linical syndrome of cognitive, motor and behavioural dysfunction
Antinori et al., 2007). These neurological complications arise
ost likely due to the early penetration of HIV-1 into the CNS via
nfected immune cells such as CD4+ T lymphocytes, dendritic cells,
onocytes and macrophages, which are all cellular reservoirs of
IV-1 (Valcour and Paul, 2006; McArthur, 2004; Blankson et al.,
002). A key feature of HIV populations in the CSF is that initially
hey may be identical to that in the plasma, but as the infection
rogresses the viral populations diverge, with the greatest diver-
ence being observed in patients with HAD (Wong et al., 1997;
train et al., 2005).
In the late stages of AIDS, the CNS is also vulnerable to several
evere opportunistic diseases including cryptococcal meningitis
ndprimaryCNS lymphoma.All theseneurological conditionswere
nitially associated with high morbidity and mortality, and this
ontinues to be the situation in resource-poor countries where
ighly active antiretroviral therapy (HAART) is not readily avail-
ble (Table 1). However, where there is wide-spread use of HAART
here has been a profound reduction in the incidence/severity of
AD (d’Arminio et al., 2004) and themajor CNSopportunistic infec-
ions, although the prevalence of minor HIV-1 associated cognitive
mpairment appears to be rising. Various factors including tox-
able 1
ntiretroviral drugs currently approved by the US Food and Drug Administration for the
nti-HIV drugs.
RTIs NNRTIs NtRTIs PIs
idovudine Efavirenz Tenofovir Saquinavir
AZT) Nevirapine (PMPA) Ritonavir
alcitabine Delaviridine Amprenavir
ddC) Indinavir
idanosine Nelﬁnavir
ddI) Lopinavir
tavudine Atazanavir
d4T) Fosamprenavir
bacavir Tipranavir
mtricitabine Darunavir
FTC)
amivudine
3TC)
ian et al. (2009) and Kline and Sutliff (2008).
a Fusion inhibitor.
b Currently in clinical trials.
c CCR5 inhibitor.Ritonavir Amprenavir
Saquinavir Fosamprenavir
Enfuvirtide Atazanavir
Indinavir
icity, insurgence of drug resistance, poor medication adherence
and sometimes limited access to HAART, contribute to this phe-
nomenon. It has also been speculated that the constant presence
of HIV and the associated immunoactivation and inﬂammation in
CSF is linked to this more subtle form of brain injury. As elevated
viral loads in the CSF, predict subsequent neuro-cognitive impair-
ments (Ellis et al., 2002). Overall it would suggest that treatment
of CNS disease associated with HIV-infection may be sub-optimal
and clinical data has suggested that the CNS effectiveness of anti-
HIV drug regimens can be signiﬁcantly improved by treating with
CSF-penetrating antiretroviral drugs in patients with cognitive
impairments (Letendre et al., 2004, 2008a,b).
The classiﬁcation of the antiretroviral drugs into either low-CNS
penetration (rank 0), intermediate CNS penetration (rank 0.5) or
high-CNS penetration (rank 1) was based on extensive literature
reviews and considered the physico-chemical characteristics of the
drug, measured CSF concentrations and effectiveness in the CNS
(Table 2) (Letendre et al., 2008a). Drug combinations are ranked100 L. Varatharajan, S.A. Thomas / Antiviral Research 82 (2009) A99–A109
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ranking for drug combinations does not allow for other drug prop-
erties, such as drug interactions at the blood–CNS interfaces to be
considered, and these factors may actually contribute to lack of,
or in fact enhanced, CNS efﬁcacy of speciﬁc drug combinations.
treatment of HIV infection. HAART comprises the combined use of three or more
Integrase inhibitors Entry inhibitors Maturation inhibitors
Raltegravir Enfuvirtidea Bevirimatb
Maravirocc
L. Varatharajan, S.A. Thomas / Antiviral Research 82 (2009) A99–A109 A101
Fig. 1. Permeation mechanisms across the BBB: (1) paracellular diffusion between the cells of the capillary endothelium. (2) Transcellular diffusion; solutes with sufﬁcient
lipid solubility may passively diffuse through the cell membranes of the endothelial cells and enter the brain. (3) Carrier-mediated transport of more hydrophilic molecules is
via SLCs inserted into the luminal and/or abluminalmembrane. Thesemaybe (a) facilitated bi-directional carriers operating in the direction of the concentration gradient, (b/c)
uni-directional into or out of the cell (d) co-transporters/exchangers co-transporting or exchanging another solute or ion in the same or opposite direction. (4) Active efﬂux
c lutes
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ranscytosis can also occur whichmay be non-speciﬁc (ﬂuid phase, very limited at th
hich involves an electrostatic interaction between a positively charged substance
RMT), which involves a receptor (Rc) and is highly selective for speciﬁc molecules.
ecent progress strongly suggests that certain transporters in the
BB impede the access of anti-HIVs to the CNS and that pharma-
ological modulation of these transporters could be used to our
dvantage (Eilers et al., 2008).
In order to examine drug interactions at the transporter level
f the blood–CNS interfaces in more detail, a clear picture of drug
ovement into the CNS is clearly warranted. This may prove useful
n ﬁne-tuning this ranking scheme and is the focus of this review.
e will start with a summary of current anti-HIV drugs and how
olecules are restricted from crossing the blood–CNS interfaces.
his will then be followed by a brief overview of those membrane
ransporters considered to be relevant to the disposition and effec-
iveness of nucleoside reverse transcriptase inhibitors (NRTIs), non-
ucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide
everse transcriptase inhibitors (NtRTIs) and protease inhibitors
PIs). Possible future research directions will then be discussed.
. Anti-HIV drugs
According to US and British guidelines, the goal of HIV ther-
py must always be to achieve a viral load of <50 copies/mL within
–6 months of starting treatment (Gazzard, 2008; Department of
ealth and Human Services, 2008). Traditionally, the main classes
f anti-HIV drugs used include NRTIs, NNRTIs, NtRTIs and PIs
Table 1). However, other classes are also available including inte-
rase inhibitors and entry inhibitors such as fusion and CCR5
nhibitors (Qian et al., 2009). HAART comprises the combined use
f three or more anti-HIV drugs. The current recommended ﬁrst
ine of treatment is a NNRTI, efavirenz, with the nucleoside back-
one Truvada® (emtricitabine and tenofovir disoproxil fumarate)
nd Kivexa® (abacavir and lamivudine) (Gazzard, 2008).. Blood–brain and blood–CSF barriers
Substances can cross non-barrier capillary walls by a variety
f routes, either between the cells of the endothelium (paracel-either from the cytoplasmic compartment or directly from the cell membrane. (5)
) or speciﬁc. Speciﬁcmechanisms include absorptive-mediated transcytosis (AMT),
he negatively charge plasma membrane surface, or receptor-mediated transcytosis
lular movement), directly through the cell wall (active transport,
facilitated and/or passive diffusion) or through vesicular transport
(endocytosis). However, the cerebral capillaries are the site of the
blood–brain barrier (BBB) and consequently these three routes are
restricted by the presence of tight junctions between the endothe-
lial cells, the lack of intracellular fenestrations in brain endothelial
cells, the paucity of endocytotic vesicles as well as by the pres-
ence of multiple metabolic enzymes and diverse transport systems
(Fig. 1). Thus the entry of anti-HIV drugs/substances by unregulated
pathways or by leakage is limited.
In addition, the choroid plexus acts as a barrier between the
circulating blood and cerebrospinal ﬂuid (CSF) and is also the site
of production of the latter. They are located in the lateral, third
and fourth ventricles and their barrier function is attributed to
the tight junctions between the epithelial cells, in addition to the
metabolismand efﬂux that occurswithin the tissue itself (Strazielle
et al., 2004). However, themolecular composition of the intercellu-
lar junctional complexes and the transporters present at the BBB
(Gazzin et al., 2008) differ from that on the blood–CSF barrier,
which means that drug movement into the brain varies depend-
ing on its main route of entry. Consequently, although the CSF is
an accessible body ﬂuid that provides insight into the brain infec-
tion and drug penetration, it can also diverge in important ways
from the brain itself. An understanding of anti-HIV drugmovement
across both theBBBand theblood–CSFbarrier is therefore of special
interest.
4. Transporters
A large spectrum of transporters exist for different substrates
and following the sequencing of the human genome it is believed
that approximately 500–1200 genes encode drug transporters
(Sakaeda et al., 2004). These carriers have been classiﬁed into two
main groups, designated the ATP-binding cassette (ABC) trans-
porters and the solute-carrier (SLC) superfamily (Loscher and
Potschka, 2005).
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.1. ABC transporters
ABC transporters are the most extensively studied group, which
re responsible for the cellular extrusionof a varietyofmolecules by
sing energy produced from ATP hydrolysis (Loscher and Potschka,
005). P-Glycoprotein (P-gp) (also known as MDR-1 or ABCB1)
s the most characterised ABC transporter. Other members of
he superfamily include multi-drug resistance-associated proteins
MRPs) (also referred to as ABCC transporters) and breast can-
er resistance protein (BCRP) (also known as ABCG2). Recent
tudies have demonstrated that the expression of these trans-
orters at the BBB and on other cells such as lymphocytes,
D4+ T cells and microglia, play a crucial role in permitting the
ntry of anti-HIV drugs into cellular and anatomical reservoirs of
IV-1.
.1.1. P-gp
P-gp, ﬁrst discovered in 1976, is a 150–180kDa membrane pro-
ein encoded by the multi-drug resistance gene 1 (MDR-1). It is
idely expressed in tissues such as the liver, kidney and intes-
ine, as well as the luminal membrane of the BBB (Cordon-Cardo
t al., 1989; Jette et al., 1993, 1995; Soontornmalai et al., 2006)
nd the choroid plexus epithelium (Rao et al., 1999; Gazzin et
l., 2008). At the BBB it appears to be important in protect-
ng the brain from hydrophobic molecules and drugs. However,
ts function at the blood–CSF barrier is ambiguous and it may
ot have a major neuroprotective role at this site (Gazzin et al.,
008). Uncharged or weakly basic molecules are most efﬁciently
ransported by P-gp, but acidic compounds can also be trans-
orted. A large body of evidence suggests that PIs are substrates
f P-gp and as a result the limited ability of these drugs to trans-
erse the blood–brain barrier is attributed to the activity of this
fﬂux transporter (Kim et al., 1998; Polli et al., 1999; Choo et al.,
000; Park and Sinko, 2005; Bachmeier et al., 2005; Eilers et al.,
008).
In comparison to PIs, the interaction of P-gp and NRTIs has been
ess extensively studied. Recently a study provided in vivo and in
itro evidence that the nucleoside reverse transcriptase inhibitor,
bacavir ([(−)-(1S, 4R)-4-[2-amino-6 (cyclopropylamino)-H-purin-
-yl]-2-cyclopentene-1-methanol; 1592U89]) is a P-gp substrate
Shaik et al., 2007; Giri et al., 2008). In fact it is likely that P-
p is the dominant transporter limiting the CNS penetration of
bacavir (Giri et al., 2008). Similarly, earlier studies showed that
oth HIV-infected T cell and monocytic cell lines had increased
-gp expression which accumulated signiﬁcantly less zidovu-
ine (azidodeoxythymidine (AZT)) in comparison to uninfected
ells (Gollapudi and Gupta, 1990). Likewise, a decrease in AZT
ccumulation in P-gp-over-expressing CEM VBL100 cells with a
orresponding decline in antiviral efﬁcacy of the drug has been
bserved (Antonelli et al., 1992).
Using P-gp in Caco-2 cell lines, theNNRTIs nevirapine, efavirenz,
nd delavirdine were found not to be substrates of this transporter.
owever, all of thesedrugswere found to induce the expression and
unction of P-gp, with nevirapine being the more potent inducer
ompared with the other two NNRTIs (Stormer et al., 2002). Alter-
atively, a recent study demonstrated that the effect of P-gp on
ntracellular HIV-1 replicationmay bemore clinically relevant than
he efﬂux function of P-gp on PIs. The data suggested that high-
ellular P-gp activity corresponds with a lower intracellular HIV-1
oad in vivo (Sankatsing et al., 2007). Interestingly, Langford et al.
2004) showed that AIDS patients with HIV encephalitis (HIVE)
ave higher brain P-gp levels than HIVE-negative patients. How-
ver, despite studies showing an upregulation of P-gp in HIV-1
nfectedmacrophages, CD4+ T lymphocytes andglial cells (Langford
t al., 2004), the pump function of P-gp in HIV-1 infected patients
s thought to be decreased (Sankatsing et al., 2004).l Research 82 (2009) A99–A109
Recent experiments using primary culture of rat astrocytes have
demonstrated that both the expression and the transport function
of P-gp are downregulated following exposure toHIV viral envelope
protein, gp120. Collectively, these crucial glial cells that harbour the
virus within the CNS are thought to form a dynamic barrier behind
the BBB to further impede the access of anti-HIV drugs to sites of
infectionwithin the CNS (Ronaldson and Bendayan, 2006). Further-
more, using intact, isolated rat brain capillaries, Hartz et al. (2004)
revealed that subnanomolar to nanomolar concentrations of the
hormone endothelin-1 (ET-1) rapidly and reversibly attenuated P-
gp-mediated transport function over the short term (minutes). This
effect was found to be due to the stimulation of the ETB recep-
tor with subsequent activation of nitric oxide synthase and protein
kinase C. The release of ET-1 has been apparent in a number of CNS
disorders including HIVE (Hartz et al., 2004) and AIDS dementia
complex however the effect of ET-1 on brain capillary permeability
remains controversial, with some studies claiming that ET-1 sig-
niﬁcantly increases brain permeability and others suggesting no
effect. This discrepancy can be attributed to the different durations
of the experiments. An increase in permeability was observed over
hours todays, raising thepossibility that capillarypermeabilitymay
remain unchanged during early ET-1 exposure (Hartz et al., 2004).
Inﬂammation is a central pathophysiological mechanism in the
majority of CNS diseases and is reproduced experimentally by
the injection of the bacterial endotoxin—lipopolysaccharide (LPS).
Altered P-gp expression and corresponding changes in the dispo-
sition of several xenobiotics have been observed in the LPS model
(Miller et al., 2008). Recent studies have demonstrated evidence in
line with these ﬁndings. P-gp was downregulated via an unknown
mechanism following the administration of LPS into rat intracra-
nial ventricles. This subsequently caused an accumulation of the
P-gp substrate, digoxin, within the brain (Goralski et al., 2003).
Other studies have shown that the proinﬂammatory cytokine TNF-
 causes a rapid and reversible loss of P-gp activity in rat brain
capillaries.
The proposed mechanism suggested that short-term exposure
to the cytokine caused TNF receptor 1 stimulation resulting in ET-
1 release and consequent ETB receptor, nitric oxide synthase and
protein kinase C activation. This pathway was thought to be acti-
vated by LPS to reduce P-gp transporter activity (Hartz et al., 2006).
More recently, the same research group found that this initial rapid
decrease in transport preceded a2–3-hplateau at this reduced level
of transporter activity, and was then followed by a rapid increase
in both transporter activity and protein expression. Collectively,
these ﬁndings demonstrate that chronic inﬂammation can tighten
the BBB to CNS drugs which are P-gp substrates by upregulat-
ing P-gp expression (Bauer et al., 2007). An upregulation of P-gp
in rat brain endothelium was also observed in an inﬂammatory
pain model causing a decrease in the penetration of the P-gp sub-
strate, morphine and consequent antinociception (Seelbach et al.,
2007).
HIV-Tat, a protein thought to be responsible for the vascular
abnormalities and neurotoxicity inHIV, also induces the expression
of P-gp in brain endothelial cells which correlated with a func-
tional upregulation of the transporter function of P-gp (Hayashi et
al., 2005). A similar change in P-gp expression has been observed
following chronic exposure of bovine brain microvessel endothe-
lial cells to ritonavir. In fact, the HIV PI increased P-gp activity and
expression in a concentration-dependent manner in this in vitro
model of the BBB, raising the possibility that HAART could itself
contribute to the brain as a HIV sanctuary site by the induction
of drug transporters (Perloff et al., 2007). Collectively, these stud-
ies suggest that the selective inhibition of P-gp may facilitate the
entry of PIs and certain NRTIs into viral sanctuaries and enhance
the concentration of anti-HIV drugs in these sites to therapeutic
levels.
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.1.2. MRPs
MRPs are ATP-driven efﬂux transporters. Those localised at the
uminal membrane of the brain capillary endothelial cells (i.e.
rp5) contribute to the non-permissive nature of the BBB (Dallas
t al., 2006). However, evidence also exists for an abluminal (Mrp1)
nd possibly cytoplasmic (Mrp2) expression of speciﬁc isoforms
Soontornmalai et al., 2006). Currently, direct evidence exists only
or the expression of MRP-1, MRP-2, MRP-4 and MRP-5 at the
BB (Dallas et al., 2006; Soontornmalai et al., 2006; Eilers et al.,
008) and of Mrp1 and Mrp3 (but not Mrp5) at the choroid plexus
Soontornmalai et al., 2006). Interestingly the choroid plexus, but
ot the BBB, is the main site of blood-facing, Mrp1-dependent cel-
ular efﬂux from the rat brain (Gazzin et al., 2008).
MRPs are known to co-transport drugs with glucuronide, glu-
athioneor sulphate. Amongst theninemembers of this transporter
amily (MRP1–9), the ﬁrst ﬁve (MRP-1, MRP-2, MRP-3, MRP-4 and
RP-5) are frequently associated with the efﬂux of therapeutic
gents. MRP-1, MRP-2 and MRP-3, transport hydrophilic anionic
ompounds, large molecules and peptidomimetics (Dallas et al.,
006); however, both MRP-4 and MRP-5 transport small polar
ompounds such as nucleosides, cyclic nucleotides and nucleoside
nalogs (Schuetz et al., 1999; Wijnholds et al., 2000).
The HIV PIs saquinavir, ritonavir and lopanivir were found to
e substrates of MRP-1 and MRP-2 and therefore these trans-
orters may also contribute to the limited penetration of PIs into
he brain (Bachmeier et al., 2005; Park and Sinko, 2005; Janneh
t al., 2005, 2007; Eilers et al., 2008). A recent in vitro study
emonstrated that MRP-1, MRP-2 and MRP-3 were also inhib-
ted in a concentration-dependent manner by NNRTIs (delavirdine,
favirenz and nevirapine), NRTI (abacavir, emtricitabine and
amivudine) and the NtRTI, tenofovir. This inhibition was particu-
arly apparent for delaviridine, efavirenz and emtricitabine (Weiss
t al., 2007). In addition, MRP-4 and MRP-5 are thought to be low-
fﬁnity transporters of nucleoside-based antiretrovirals (Schuetz
t al., 1999; Wijnholds et al., 2000) and both have been implicated
n the rapid removal of zidovudine from human brain microves-
el endothelial cells (Eilers et al., 2008). Previous studies have
lso suggested an association between MRP-4 over-expression and
ncreased efﬂux of nucleoside-based anti-HIV drugs (Schuetz et
l., 1999). A previous in vitro study revealed that ritonavir induces
he expression of MRP-1 in a concentration-dependent manner,
owever this was noted in human colon in adenocarcinoma cells
Gimenez et al., 2004). MRP-1 is also thought to promote HIV repli-
ation (Speck et al., 2002).
.1.3. BCRP
BCRP is a novel ABC-transporterwhich is localised in various tis-
ues including cerebral endothelial cells (Eisenblatter et al., 2003).
t is believed to have a similar tissue localisation to P-gp (Fig. 1).
Is such as ritonavir, saquinavir and nelﬁnavir have found to be
ffective inhibitors, but not substrates of this transporter (Gupta
t al., 2004). Studies have also found that BCRP is a cellular factor
nvolved in the resistance to NRTIs. For example, the accumulation
nd anti-HIV activity of AZT was signiﬁcantly reduced by dimin-
shing its metabolites, in cells overexpressing BCRP and this was
eversed by fumitremorgin C, a BCRP inhibitor, suggesting that AZT
s a substrate of BCRP (Wang and Baba, 2005; Wang et al., 2004).
More recently, a murine homolog of human BCRP was used to
nvestigate the contribution of BCRP in the directional transport
f abacavir and AZT. Their data provided evidence suggesting that
oth these drugs are substrates for Bcrp1 and further directional
ransport studies conﬁrmed the role of Bcrp in the polarised trans-
ort of both abacavir and AZT in vitro (Pan et al., 2007). However,
n vivo results showed that deletion of Bcrp1 has little inﬂuence
n the brain penetration or overall disposition of AZT and only
moderate effect on abacavir (Giri et al., 2008). Overall, ﬁndingsl Research 82 (2009) A99–A109 A103
from these studies suggest that BCRP could contribute to drug–drug
interactionsobserved in vivo followingHAART. The roleof this efﬂux
protein during co-administration of anti-HIV drugs that are either
substrates, inhibitors or both of BCRP, could be very valuable for the
delivery of HAART to viral sanctuary sites.
4.2. The SLC superfamily
A large body of evidence demonstrates that the solute carrier
(SLC) superfamily plays a crucial role in the efﬂux transport of
organic compounds, organic anions particularly, across the BBB
(Kusuhara and Sugiyama, 2005). Some members of this superfam-
ily includeorganic anion-transportingpolypeptide (OATPs), organic
anion transporters (OATs) and organic cation transporters (OCTs).
These ATP and sodium-independent polypeptides are expressed in
a variety of tissues including the brain capillary endothelium and
choroid plexus epithelial cells and regulate the movement of drugs
through the brain barriers.
4.2.1. OATPs
All Oatp/OATPS are members of the SLC21 family and 36
Oatps/OATPS have so far been identiﬁed in humans, rats and mice
(Hagenbuch and Meier, 2004). Several studies have shown that
these transporters have a role in the efﬂux of organic compounds.
The expression of OATP1A2 and OATP1C1 have been found in
the BBB and the brain, respectively. In rats, Oatp1a4, Oatp1a5
and Oatp1c1 are expressed at the BBB and the blood–CSF barrier
(Kusuhara and Sugiyama, 2005). OATP has been implicated in the
removal of 2′3′-dideoxycytidine (ddC; zalcitabine) from the brain
and CSF (Gibbs and Thomas, 2002). Oatp2 is found at the cerebral
capillary endothelium and the choroid plexus epithelium, suggest-
ing a role for these carriers in the transport of drugs between the
blood and CNS compartments (Gao et al., 1999). An Oatp-2 like
transporter has been implicated in the uptake of the NRTIs, 2′,3′-
dideoxyinosine (ddI, didanosine) and (−)-2′-deoxy-3′-thiacytidine
(3TC, lamivudine) into the choroidplexus (GibbsandThomas, 2002;
Gibbs et al., 2003a,b). HIVmay enter the CNS via the choroid plexus
and therefore transporters present at this site could play an impor-
tant role in CNS efﬁcacy of certain drugs.
4.2.2. OATs
This family of transporters comprise OAT1, OAT2, OAT3, OAT4
and RST. UST1, UST3 and OAT5 are also considered as transporters
of organic anions, however this has not yet been proven (Anzai et
al., 2006). The recently identiﬁed urate transporter, URAT1 is very
similar to RST in terms of amino acid sequence and tissue distri-
bution. Additionally, URAT1 appears to be the human ortholog of
murine RST and rat OAT1 (Eraly et al., 2004). Many drugs exist as
organic anionsatphysiologicalpH levels and thereforeOATspresent
musthaveapivotal role inhandling these compounds. Studiesusing
Xenopus laevis oocytes showed that antiretroviral nucleoside drugs
are substrates for OAT proteins despite the fact that they are not
conventional organic anions (Strazielle et al., 2003).
Oat3 is present in the rat brain capillaries (Ohtsuki et al., 2002).
There is no direct evidence for the expression of Oat1 at the BBB,
however, it is suggested that the observed efﬂux of certain sub-
stances known to be Oat1 substrates from brain to blood indicates
that the presence of Oat1 is likely (Sun et al., 2003). ddC and AZT
are thought to be removed from the brain by a member of the OAT
family (Takasawa et al., 1997; Gibbs and Thomas, 2002; Strazielle et
al., 2003). OAT1 and 3 are expressed in the human, murine and rat
choroid plexus (Sweet et al., 2002; Alebouyeh et al., 2003) and seem
to be largely important in determining the availability of organic
anions in the CSF (Eraly et al., 2004). These isoforms are likely
candidates for the uptake of CSF-borne AZT and ddC (Gibbs and
Thomas, 2002; Strazielle et al., 2003). However, the efﬂux of AZT
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as inhibited by speciﬁc inhibitors of both of these transporters,
hich makes it difﬁcult to attribute a particular isoform to this
ffect.
Anthonypillai et al. (2006) investigated the distribution of a pro-
rug of the NRTI tenofovir, known as PMPA to the brain, CSF and
horoid plexus. Interestingly, the entry of this pro-drug into the
rain was negligible, but it could reach the CSF. The presence of a
ransporter at the level of the choroid plexus was indicated. Since
OAT1 and hOAT3 are high- and low-afﬁnity transporters of PMPA,
espectively (Cihlar et al., 2001; Izzedine et al., 2005), the involve-
ent of these carriers was speculated however no detectable
nteraction was observed (Anthonypillai et al., 2006).
.2.3. OCTs
The literature concerning OCT expression in the brain is at
imes contradictory, and thismaybe the result of variation between
pecies and also differing area and levels of expression of the trans-
orters within the brain (Sweet et al., 2001). A study by Slitt et
l. (2002) found that mRNA for all ﬁve organic cation transporters
ould be detected in the rat brain. Although this work did not eval-
ate whether the transporters were present at the brain barriers,
dditional studies have provided some evidence for the presence
or individual organic cation transporters at the BBB and choroid
lexus. It has been established that OCTN2 is found on the luminal
ace (and possibly the abluminal face too) of the cerebral capillary
ndothelial cells of humans, rats, pigs and cows (Kido et al., 2001).
CT2, OCT3, OCTN1 and OCTN2 (but not OCT1) are also expressed
n the rat choroid plexus (Sweet et al., 2001). Human OCTs play a
rucial role in the initial step involved in hepatic or renal excre-
ion of many cationic compounds. Furthermore, previous studies
ave demonstrated the involvement of rat OCTs and an undeﬁned
rganic cation-proton exchanger in the cellular uptake of AZT and
TC, raising the possibility that human OCTs could also be involved
n the uptake of anti-HIV drugs (Minuesa et al., 2008). Moreover,
inuesa et al. (2008) revealed that hOCTs were heterogeneously
xpressed in primary lymphocytes, monocytes, macrophages and
endritic cells. These transporterswere also upregulatedupon lym-
hocyte activation.
A recent study suggested that the PIs, nelﬁnavir, ritonavir,
aquinavir and indinavir are possibly inhibitors of OCT1 and OCT2
Jung et al., 2008). This supported evidence provided by Zhang et al.
2000) that some HIV PIs may be potent inhibitors of cationic drug
ptake, but poor substrates for human OCT1 (Zhang et al., 2000).
urthermore, the NRTIs, lamivudine and zalcitabine are substrates
f OCT1 and OCT2 (Jung et al., 2008). Moreover, when assessing the
xpression of OCTs in lymphnodes of HIV-infected patients in com-
arison to healthy controls, Jung and colleagues found that OCT1
nd OCT2 were upregulated in the lymph nodes of HIV-infected
atients, indicating that the accumulation of OCT substrates would
e much higher in the lymph nodes of these patients. This could be
ue to the activation of the immune system and effects of cytokines
nduced by HIV infection (Jung et al., 2008). This study implies that
sound knowledge of OCTs is crucial in understanding both drug
nteractions thatmay occur with HAART and also the role they play
n regulating drug transport.
.3. Nucleoside transporters
There are two main types of nucleoside transporters, classiﬁed
s low-afﬁnityequilibrative (SLC29) andhigh-afﬁnity concentrative
SLC28), which are known to transport certain NRTIs..3.1. Equilibrative nucleoside transporters (ENTs)
There are four members of the SLC29 family. hENT1, the ﬁrst
haracterised family member, shares similar substrate speciﬁci-
ies with hENT2. These transporters play a pivotal role in thel Research 82 (2009) A99–A109
uptake of nucleoside and nucleobases across a membrane down
their concentration gradient. Based on their sensitivity to nitroben-
zythioinosine, ENTs are subdivided into equilibrative sensitive (es)
and equilibrative insensitive (ei) (Baldwin et al., 2004; Thomas,
2004).
ENT1 protein, which encodes the es nucleoside transporter,
is present on the human BBB. It is thought that this carrier is
responsible for the transport of ddI across the guinea pig BBB.
This was conﬁrmed when the es transporter substrates, adenosine
and thymidine, inhibited the brain uptake of [3H]ddI (Gibbs et al.,
2003a). Interestingly, the es transporter is also active inhuman lym-
phocytes, raising the possibility that it could facilitate the transport
of NRTIs into this HIV reservoir (Chan et al., 1993). ENT2, the ei
transporter, transports purine and pyrimidine nucleosides butwith
a lower afﬁnity that ENT1. However unlike ENT1, ENT2 is a carrier
of AZT and can transport ddI and ddC much more efﬁciently than
ENT1 (Baldwin et al., 2004).
Recently, Minuesa et al. (2008) found that human ENTswere the
most highly expressed transporters in peripheral blood mononu-
clear cells and CD4+ T-cells and that the expression and activity of
this transporter were increased by 100- and 30-fold, respectively,
following stimulation of primary T lymphocytes. Determining the
isoform responsible for anti-HIV drug transport across cell mem-
branes would prove valuable in targeting these drugs to infected
cells and in understanding drug–drug interactions and therapy fail-
ure (Minuesa et al., 2008).
4.3.2. Concentrative nucleoside transporters (CNTs)
There are three subtypes of sodium-dependent CNTs (CNT1–3)
in the SLC28 family. CNT1 is a pyrimidine speciﬁc transporter
whereas CNT2 is a purine-preferring transporter which also has
the ability to transport uridine. CNT3 is a broad selective nucleo-
side transporter (Gray et al., 2004). These transporters have been
identiﬁed in the liver, intestine, kidney and choroid plexus. Redzic
et al. (2005) demonstrated the presence of rENT1, rENT2 and rCNT2
mRNA and protein in primary cultures of rat brain endothelial cells
and rat choroid plexus epithelial cells. rCNT3 was present at the
transcript level in choroid plexus epithelium. Furthermore, they
showed that the concentrative transport of nucleosides was asso-
ciated exclusively with themembrane that faces brain ﬂuids in situ,
suggesting a role of these barriers in extruding nucleosides from
the brain (Redzic et al., 2005).
Using rat and human tissues, CNT and ENT cDNAs were cloned
and their functional characterisation was determined using Xeno-
pus oocytes. This study revealed that CNT1, CNT3 and ENT2 but
not CNT2 or ENT1 transported AZT but with a much lower afﬁnity
than endogenous nucleosides. In addition, the inﬂux of AZT into the
CSF through choroid epithelial cells was found to be unaffected by
endogenous nucleosides (Yao et al., 2001; Strazielle et al., 2003).
CNT has also been implicated in the transport of ddI across the
BBB (Li et al., 2001). However, the role of human CNT1 as a uptake
transporter for ddI and stavudine (d4T) has remained controver-
sial, as some researchers have described such a function for hCNT1
whereas others (Minuesa et al., 2008; Chishty et al., 2004; Chang et
al., 2004; Cano-Soldado et al., 2004) have argued that hCNT1/2 (and
even hENT1) have a low afﬁnity for these drugs due to the absence
of the 3′OH group in the ribose ring of the structure of nucleoside
analogs. Conversely, hCNT3 appears to be an efﬁcient transporter
of AZT, ddC and ddI (Minuesa et al., 2008).5. Other aspects
BBB disruption during HIV infection is thought to provide a pri-
mary portal for infected cells to enter the brain and to contribute
signiﬁcantly to neuropathology such as HIVE and HAD (Toborek et
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l., 2005;Wang et al., 2008). Several processes have been attributed
o the disruption of the BBB in HIV infection, in addition to those
iscussed earlier. Morphological changes such as an increase in
he diameter of cortical vessels as well as alterations such as
he thinning of basal lamina and loss of glycoproteins present in
ndothelial cells are all features of the disrupted BBB observed in
IV-infected patients. Furthermore, apoptosis of endothelial cells
nd tight junction disruption are thought to be other mechanisms
y which the integrity of the BBB is impaired in HIV (Toborek et al.,
005).
HIV infection is also associated with a wide range of vasculi-
ides including that affecting small, medium and large vessels and
ne common feature amongst all vasculitides seen in HIV infec-
ion is the underlying inﬂammation of the vessel wall (Guillevin,
008). A recent study has also indicated that HIV-1 increases the
ensitivity of the BBB to disruption by systemic lipopolysaccharide,
hich is elevated in HIV-1-infected individuals (Wang et al., 2008).
urthermore, monocytes that were infected with HIV-1 provirus
ere more able to cross the BBB particularly after lipopolysaccha-
ide administration. Interestingly,HAARThasbeen shown to reduce
he elevated systemic levels of lipopolysaccharide present in HIV-
-infected individuals (Brenchley et al., 2006). It has thus been
uggested that HAART may reduce the incidence of HAD by not
nly reducing HIV-1 replication but also by reducing circulating
ipopolysaccharide and thereby reducing compromise of the BBB
nd migration of HIV-1-infected monocytes from the systemic cir-
ulation into the brain (Wang et al., 2008). However, it may also
e that disruption of the brain barriers facilitates the entry of drugs
nto the CNS and consequently alleviates the symptomsofHAD. The
otential toxic effects this may have due to excessive drug concen-
rations accessing the brain (see below) or other unknown effects
recipitated by higher concentrations of anti-HIV drugs in the CNS
re important factors that remain to be explored (Toborek et al.,
005; Gimenez et al., 2004).
Both in vitro and in vivo studies, as well as clinical obser-
ations, have shown that conventional anti-HIV drugs can have
igniﬁcant toxic effects. HAART has been directly associated with
he development of endothelial dysfunction and consequently
ith cardiovascular diseases. Clinical toxicities of NRTIs include
eripheral neuropathy, skeletal myopathy, lactic acidosis and
yperlactatemia (Kline and Sutliff, 2008). There are two types of
NS adverse reactions associatedwith HAART (1) direct drug toxic-
ty and (2) immunopathology related to immune restoration and
oxicity (Price and Spudich, 2008). Although there is little evi-
ence to suggest that NRTIs and PIs have direct adverse effects
n the CNS, the NNRTI efavirenz clearly affects CNS function, and
ts use is complicated by neuropsychiatric symptoms such as dys-
horic dreams. Additionally, one report suggested an interactive
ffect of efavirenz and tenofovir on neuropsychiatric symptoms,
hich were however, fully reversible following the cessation of
reatment (Price and Spudich, 2008). Furthermore, a recent study
as revealed that prolonged HAART usage and aging may play a
ole in the overall increase in amyloid deposition in HIV demen-
ia mediated by either inhibition of insulin degradation enzyme or
isrupted amyloid precursor protein transport (Nath and Sacktor,
006).
Recently the term “Immune reconstitution inﬂammatory syn-
rome” (IRIS) has been created to recognise the improvement of
he immune system generally seen a few weeks after the initiation
f HAART. Paradoxically, IRIS also results in a decline in clinical sta-
us and is predominantly associated with a huge rise in the CD4
-lymphocyte count as well as a reduction in the peripheral HIV
NA viral load. If IRIS is untreated and affects the CNS, then it is
ssociated with signiﬁcant morbidity and mortality. Recently, IRIS
atally affected two patients with HIV dementia, despite control of
he virus in the periphery (Nath and Sacktor, 2006).l Research 82 (2009) A99–A109 A105
6. Conclusion and future directions
The HIV/AIDS pandemic has lasted almost 3 decades, and a
wide range of anti-HIV drugs have been developed in an attempt
to ameliorate the infection and ultimately eliminate this highly
fatal disease. To tackle HIV and prevent the formation of viral
sanctuary sites, antiretroviral drugs must be able to access the
brain. However the normal function of the BBB and blood–CSF
barrier to shield the brain from harmful substances and provide
a precisely regulated unique environment in the CNS, hinders
the penetration of anti-HIV drugs into the brain, promoting viral
replication, the development of drug resistance and ultimately sub-
therapeutic concentrations of drugs reaching the brain, leading
to therapeutic failure. Consequently, Letendre’s CNS penetration-
effectiveness ranking concept for quantifying antiretroviral drug
penetration into the CNS is clearly worthy of serious consid-
eration as an additional tool in designing more effective drug
treatment strategies (Letendre et al., 2008a). However, it is impor-
tant that the actual raw information that was used to determine
each drug’s individual rank becomes available, so that the ranking
scheme could be further and more easily enhanced by consider-
ing drug–drug interactions at the level of blood–CNS interfaces
and possibly other factors (e.g. toxicity issues) as they come to
light.
The plethora of transporters expressed at the brain barriers all
act as selective gatekeepers, and this remains a major obstacle for
antiviral therapy. Multi-drug transporters have overlapping sub-
strate speciﬁcity for numerous hydrophobic compounds and there
seems to be considerable overlap in the efﬂux transporters used by
certain anti-HIV drugs raising the possibility that inhibiting more
than one transporter at a timemay be one approach to improve CNS
delivery of anti-HIV drugs. Although certain studies have demon-
strated that simultaneously inhibiting multiple transporters can
augment the concentration of anti-HIV drugs in the CNS, thiswould
not appear to be a viable strategy, because it leaves the brain sus-
ceptible to damage by putative toxins. However, pharmacological
modulation of individual transporters by concomitantly adminis-
tering HAART with transporter-speciﬁc inhibitors may be a more
successful alternative to enhance anti-HIV drug levels in the brain,
without causing these general and systemic adverse effects (Eilers
et al., 2008).
Importantly, the relative functional importance of speciﬁc trans-
porters in individual tissues is slowly being revealed. In a recent
study by Kamiie et al. (2008) the development of a sensitive
and simultaneous quantiﬁcation method using in silico peptide
selection criteria and multi-channel multiple reaction monitoring
was implemented. By using this novel method, they were able
to determine simultaneously the absolute protein expression lev-
els of multiple membrane transporters in mouse brain capillary
endothelial cells. Consequently, a quantitative atlas of membrane
transporter proteins was constructed. Of relevance to this review,
the transporters quantiﬁed in mouse BBB were Mdr1a, Mrp4, Bcrp,
Oat3 and Oatp2 (Kamiie et al., 2008). Their ﬁndings regarding pro-
teinexpression levelswere consistentwithprevious functionaldata
(Schinkel et al., 1997). This advance in pharmacoproteomics and its
extension to human tissueswill not only provide signiﬁcant insight
into transport proteins at the BBB and other tissues, but will also
hasten the translation of preclinical work to clinical studies and
drug development (Kamiie et al., 2008).
Information regarding the interaction of anti-HIV drugs with
recently discovered novel transporters such as URAT1 and RST
are also needed, in order to acquire a complete picture of the
impediments that restrict anti-HIV drug transport across the brain
barriers. Conversely, the interaction between newer drugs, such as
Enfuvirtide and Maraviroc, and transporters also should be fully
investigated. Additionally, it would be valuable to explore whether
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hose transporters that have altered expression during HIV infec-
ion affect the penetration ofHAART across the brain barriers, and if
o, whether this can be pharmacologically modulated. Modulating
ransporters is one method by which drug delivery into the brain
ould be improved (Miller et al., 2008). Thus rather thanmodifying
ubstances inorder toallowthemtopenetrate theBBB, a reasonable
lternative strategywouldbe tomodify thepermeability of theBBB.
ecent studieshaveexplored factors responsible for themodulation
f P-glycoprotein, Mrp2 and BCRP and the signalling mechanisms
esponsible for this (Bauer et al., 2004; Imai et al., 2005; Wang et
l., 2006). Furthermore, although studies have revealed that the
ntegrity of the BBB is affected during HIV, possible strategies to
revent this have not yet been determined.
Intranasal delivery of antiretroviral drugs has been proposed
s a potential strategy to overcome the poor penetration of these
rugs into the brain and to target HIV that harbours in the CNS.
he intranasal administration of the viral entry inhibitor peptide
has recently been explored for the prevention of neuro-AIDS
evelopment such as cognitive impairment associated with HIV.
s well as being an entry inhibitor, Peptide T reduces the initial
nfection of cells expressing CCR5 receptors such asmonocytes and
icroglia and also acts as an antagonist of free gp120 and thereby
educes toxic effects (Hanson and Frey, 2007). More interestingly,
eptide T has demonstrated antiviral and immunological beneﬁts
n HIV patients receiving intranasal peptide T with decreased viral
able 3
ummary of the current understanding of transporter involvement in anti-HIV drug distr
rug name Drug class Summary
bacavir NRTI P-gp substrate. Inhibits MRP-1, MRP-2 and MRP-3 in a
concentration-dependent manner. BCRP substratea
idovudine (AZT) NRTI P-gp substrate, MRP-4 and MRP-5 substrate, BCRP subs
Removed by a member of the OAT family. OAT1 and OA
be responsible for its uptake. OCT possibly involved in
Transported by ENT2. Transported by CNT1 and CNT3
evirapine NNRTI Strongly induces the expression and function of P-gp. I
MRP-1, MRP-2 and MRP-3 in a concentration-depende
favirenz NNRTI Induces the expression and function of P-gp. Strongly i
MRP-1, MRP-2 and MRP-3 in a concentration-depende
elaviridine NNRTI Induces the expression and function of P-gp. Strongly i
MRP-1, MRP-2 and MRP-3 in a concentration-depende
itonavir PI P-gp substrate. Increased P-gp activity and expression
concentration dependent manner. MRP-1 and MRP-2 s
Induces the expression of MRP-1 in a concentration-de
manner. BCRP inhibitor. Possible OCT1 and OCT2 inhib
aquinavir PI P-gp substrate. MRP-1 and MRP-2 substrate. BCRP inhi
Possible OCT1 and OCT2 inhibitor
opanivir PI MRP-1 and MRP-2 substrate
mtricitabine NRTI Strongly inhibits MRP-1, MRP-2 and MRP-3 in a
concentration-dependent manner
amivudine (3TC) NRTI Inhibits MRP-1, MRP-2 and MRP-3 in a concentration d
manner. Oatp-2 like transporter has been implicated in
OCT possibly involved in uptake. OCT1 and OCT2 subst
enofovir (PMPA) NtRTI Inhibits MRP-1, MRP-2 and MRP-3 in a concentration d
manner. OAT1 and OAT3 are high- and low-afﬁnity tran
PMPA, respectively
elﬁnavir PI P-gp substrate. BCRP inhibitor. Possible OCT1 and OCT2
alcitabine (ddC) NRTI OATP has been implicated in its removal. Removed by a
the OAT family. OAT1 and OAT3 likely to be responsible
uptake. OCT1 and OCT2 substrate. Transported by ENT2
Transported by CNT3
idanosine (ddI) NRTI Oatp-2 like transporter has been implicated in its upta
Transported by ENT1 across guinea pig BBB. Transporte
Transported by CNT1.b Transported by CNT3
ndinavir PI P-gp substrate. Possible OCT1 and OCT2 inhibitor.
tavudine (d4T) NRTI Transported by CNT1b
mprenavir PI P-gp substrate
a Contradictory evidence also exists; see Giri et al. (2008).
b Contradicting evidence also exists; see Minuesa et al. (2008), Chishty et al. (2004), Chl Research 82 (2009) A99–A109
load in monocyte reservoirs, increased antiviral cytotoxic T-cells
with no drug-related toxicity and increased CD4 (Polianova et al.,
2003).
A fruitful area of future research will be to determine if there
are any systems that can target drug delivery to the brain and
also enable the use of recombinant protein therapeutics for this
purpose. Novel developments emerging in the ﬁeld of polymer sci-
ence and nanotechnology provide an option bywhich the obstacles
of limited brain entry can be surmounted (Kingsley et al., 2006).
Although several different polymeric materials have been explored
for localised delivery to the brain, these have been unsuccessful due
to a variety of factors such as inﬂammatory responses to implants
and their invasiveness. Despite this setback, nanomedicines such
as polyethylene glycol-coated liposomes carrying chemotherapeu-
tic drugs for systemic release have been successfully developed
and allowed for clinical use, raising the possibility that similar
methods for delivery to the brain can be developed in the near
future. Other examples of nanomaterials include nanoparticles,
polymericmicelles and nanogels (Vinogradov et al., 2004; Kabanov
and Gendelman, 2007; Begley, 2004). All have potential as drug
delivery systems targeting the brain.A number of recent studies
involving polymeric micelles and drug nanosuspensions are of par-
ticular relevance to this review.Using brainmicrovessel endothelial
cells Miller et al. (1997) showed that micelles of Pluronic copoly-
mers can affect drug transport by inhibition of P-gp and redirection
ibution at blood–CNS interfaces.
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f vesicular transport (Miller et al., 1997). Subsequently, the same
esearch group found that Pluronic P85 unimers increase accu-
ulation of a P-gp dependent drug in Caco-2 and bovine brain
icrovessel endothelial cell monolayers by inhibiting P-gp efﬂux
Batrakova et al., 1998, 2003; Kabanov and Gendelman, 2007). Fur-
hermore, Pluronic P85 inhibited substrate efﬂux via MRP1 and
RP2 (Miller et al., 1999). Spitzenberger et al. (2007) explored
he effects of Pluronic P85, antiretroviral therapy (AZT, 3TC and
elﬁnavir) or both on a severe combined immunodeﬁciency ani-
al model of HIVE. This model of HIVE involved inoculating mice
ith human monocyte-derived macrophages infected with HIV-1
Spitzenberger et al., 2007). The authors found that Pluronic P85,
s well as both the drugs and P85 combined, showed the most
igniﬁcant decrease in percentage of HIV-1 infected monocyte-
erived macrophages (8–22% of control) which was superior to
he antiretroviral drug group alone (38% of control). This study
ot only demonstrates that Pluronic P85 increases the penetra-
ion of antiretrovirals drugs into the brain but also that block
opolymers may have antiretroviral effects, particularly in cells
uch as macrophages which serve as a viral reservoir in the CNS
Spitzenberger et al., 2007). A recent study has also shown that
luronic P85 effectively inhibits the interaction of P-gp with the
Is, nelﬁnavir and saquinavir and that other transporters (including
RP)may also be inhibited by Pluronic P85 (Shaik et al., 2008).Drug
anosuspensions refer to drug particles that are often stabilised by
on-ionic PEG-containing surfactants or with mixtures of lipids.
his technology is highly advantageous, in the sense that it has
high-drug loading capacity, it is relatively simple to use and
an be applied to many drugs. One application of this technology
as in studies that used indinavir nanosuspensions for cell-
ediateddelivery to theCNS. The concept of cell-mediateddelivery
f nanocarriers to the CNS when loaded with a drug is based
pon leukocyte recruitment during an inﬂammatory response to a
athogen. In particular the process of migration, phagocytosis and
xocytosis of inﬂammatory cells such as macrophages, neutrophils
nd T cells (Kabanov and Gendelman, 2007). Indinavir nanosus-
ensions were internalised into bonemarrow derived macrophage
ysosymes and subsequently the drug was released into the extra-
ellular environment. Thus, these experiments found that indinavir
anosuspension-laden bone marrow derived macrophages were
ble to carry and release the drug in tissue (Dou et al., 2007). Fur-
hermore, a study inwhich indinavir nanosuspension bonemarrow
erivedmacrophageswere administered toHIV-1-challengedmice
emonstrated reduced numbers of HIV-infected cells in plasma,
ymph nodes, spleen, liver and lungs. The impressive result from
his study demonstrates the potential of cell-mediated delivery of
anocarriers to the brain in diseases such as HIV (Kabanov and
endelman, 2007).It would therefore be advantageous if in vivo
odels could be used to validate novel methods of drug delivery to
he brain and if genomic and proteomic techniques can be used to
dentify new blood–brain and blood–CSF barrier transporters. This
ould possibly be done if a greater emphasis is placed on themolec-
lar interaction between different transport systems in the BBB,
he toxicity induced by drug delivery technologies and molecular
maging of the brain and vasculature (Neuwelt et al., 2008).
The advent of HAART has had a profound effect on HIV/AIDS
nd its associated complications such as HAD, HIVE and MND.
owever, to further improve the morbidity associated with this
estructive pandemic, methods to circumvent the brain barriers
ust be accomplished so that sufﬁcient concentrations of anti-HIV
rugs can enter the brain. As several studies have acknowledged,
his is not an easy task and its difﬁculty, at least in part, is attributed
o the powerful transporters present at both the blood–brain and
lood–CSF barriers.Members of theABC and SLC transporter super-
amilies act in concert to protect the brain and consequently restrict
he entry of anti-HIV drugs into the brain (Table 3). Several factorsl Research 82 (2009) A99–A109 A107
add to the complexity of the problem, such as the multi-speciﬁcity
of the transporters, thediverseexpressionproﬁlesof transporters in
different tissues (e.g. the BBB compared with the choroid plexus),
the changing expression of transporters as a consequence of HIV
infection and differences between the viral populations in the CNS
and the plasma, making treatment immensely difﬁcult. A thorough
understanding of each transporter, its location, level of expression
and transport potency is needed to help improve the treatment of
HIV infection and AIDS.
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